Home Cart Sign in  
Chemical Structure| 154566-12-8 Chemical Structure| 154566-12-8

Structure of SB 204990
CAS No.: 154566-12-8

Chemical Structure| 154566-12-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SB 204990 is an effective ATP citrate lyase (ACLY) specific inhibitor that regulates lipid synthesis metabolism, suitable for related metabolic disorder studies.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SB 204990

CAS No. :154566-12-8
Formula : C18H22Cl2O5
M.W : 389.27
SMILES Code : ClC1=C(C=CC(Cl)=C1)CCCCCC[C@H](C2)OC([C@@]2(O)CC(O)=O)=O
MDL No. :MFCD28127018

Safety of SB 204990

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Hep G2 cells 30 µM 2.5 hours Inhibited cholesterol and fatty acid synthesis by 91% and 82% respectively Biochem J. 1998 Aug 15;334 ( Pt 1)(Pt 1):113-9
A2780/CDDP 30 µM 24, 48, or 72 hours SB-204990 synergized with cisplatin to reduce IC50 values Front Oncol. 2021 Mar 17;11:642229
Pkd1-null collecting duct cells (ID1-3E5) 30 µM 3 days Inhibited cystic growth, SB-204990 significantly reduced cyst area Front Mol Biosci. 2022 Nov 25;9:1001941.
Pkd1-null proximal tubule cells (PN24) 30 µM 3 days Inhibited cystic growth, SB-204990 significantly reduced cyst area Front Mol Biosci. 2022 Nov 25;9:1001941.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c male athymic nude mice Subcutaneous xenograft tumor model Intraperitoneal injection 135 mg/kg Once daily for 14 days SB-204990 greatly abolished the promoting effect of CUL3 knockdown on xenograft tumor growth Genes Dev. 2016 Sep 1;30(17):1956-70
Rats Sprague-Dawley rats Intravenous injection 150 µmol/kg Two injections, 245 and 65 minutes apart Inhibited hepatic cholesterol and fatty acid synthesis by 76% and 39% respectively Biochem J. 1998 Aug 15;334 ( Pt 1)(Pt 1):113-9
Nude mice Ovarian cancer xenograft model Intraperitoneal injection 4 mg/kg Days 7, 14, and 28, three times in total ACLY knockdown synergized with cisplatin to inhibit tumor growth Front Oncol. 2021 Mar 17;11:642229

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.84mL

2.57mL

1.28mL

25.69mL

5.14mL

2.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories